Clin Exp Vaccine Res.  2014 Jul;3(2):128-132. 10.7774/cevr.2014.3.2.128.

Seasonal influenza and vaccine herd effect

• Kim TH

• KMID: 1730616
• DOI: http://doi.org/10.7774/cevr.2014.3.2.128

Abstract

The seasonal influenza vaccine programs in many regions aimed to protect most vulnerable population, but current trivalent influenza vaccine does not provide sufficient effectiveness among people under high risk for severe outcome of the influenza. The vaccine herd effect (VHE) is the extra protection of non-immune high risk persons, with increase of immunity among vaccinated healthier persons which prevents circulation of influenza in the community. Accumulating evidences are supporting the immunization of extended population with regard to the VHE.

Keyword

Vaccine herd effect; Vaccine herd immunity; Influenza vaccine

MeSH Terms

Humans
Immunization
Influenza Vaccines
Influenza, Human*
Seasons*
Vulnerable Populations
Influenza Vaccines

Reference

1. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis. 2011; 43:683–689.

2. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010; 201:1607–1610.

3. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999; 281:908–913.

4. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 1993; 270:1956–1961.

5. Meiklejohn G, Morris AJ. Influenza vaccination. Ann Intern Med. 1958; 49:529–535.

6. World Health Organization. Fact sheet on influenza [Internet]. Geneva: World Health Organization;2009. cited 2013 Dec 1. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html.

7. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010; 59:1057–1062.

8. D'Alessio DJ, Cox PM Jr, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA. 1969; 210:485–489.

9. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12:36–44.

10. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003; 290:1608–1616.

11. Fulop T, Pawelec G, Castle S, Loeb M. Immunosenescence and vaccination in nursing home residents. Clin Infect Dis. 2009; 48:443–448.

12. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996; 18:64–76.

13. Block SL. Role of influenza vaccine for healthy children in the US. Paediatr Drugs. 2004; 6:199–209.

14. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health. 1997; 87:1944–1950.

15. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005; 165:265–272.

16. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005; 366:1165–1174.

17. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004; 292:1333–1340.

18. Englund JA. Maternal immunization with inactivated influenza vaccine: rationale and experience. Vaccine. 2003; 21:3460–3464.

19. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013; 347:f5061.

20. Glezen WP. Herd protection against influenza. J Clin Virol. 2006; 37:237–243.

21. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis. 1970; 122:16–25.

22. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001; 344:889–896.

23. Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine. 2006; 24:1047–1062.

24. Esposito S, Marchisio P, Cavagna R, et al. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine. 2003; 21:3162–3168.

25. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J. 2003; 22:10 Suppl. S207–S210.

26. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010; 303:943–950.

27. King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006; 355:2523–2532.

28. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25:860–869.

29. Wright PF. How do influenza vaccines work? Clin Infect Dis. 2004; 39:928–929.

30. Janjua NZ, Skowronski DM, Hottes TS, et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis. 2010; 51:1017–1027.

31. Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 2008; 10:1024–1029.

32. Daugherty EL, Carlson AL, Perl TM. Planning for the inevitable: preparing for epidemic and pandemic respiratory illness in the shadow of H1N1 influenza. Clin Infect Dis. 2010; 50:1145–1154.

33. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine. 2013; 31:728–731.

34. Song JY, Cheong HJ, Woo HJ, et al. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. J Korean Med Sci. 2011; 26:191–195.